https://www.selleckchem.com/pr....oducts/jr-ab2-011.ht
The effect of immunomodulatory therapy with tocilizumab for coronavirus disease 2019 (COVID-19) in real-life clinical practice remains controversial. Single-center retrospective matched cohort analysis including 47 consecutive patients treated with intravenous tocilizumab for severe COVID-19 pneumonia ("TCZ group", matched by age, comorbidities, time from symptoms onset and baseline SpO /FiO ratio with 47 patients receiving standard of care alone ("SoC group". There were no significant differences between the TCZ and SoC groups in
Like
Comment
Share
